General Nieuws OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) EN juni 10, 2021
General Nieuws OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN juni 8, 2021
General Nieuws Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD EN april 7, 2021
General Nieuws Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group EN april 6, 2021
General Nieuws Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN januari 20, 2021
General Nieuws Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN november 9, 2020
General Nieuws Regulated Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer EN oktober 13, 2020
General Nieuws Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET EN oktober 8, 2020
General Nieuws Save the date: Oxurion to host Virtual R&D Investor Day on 15 October 2020 EN oktober 5, 2020
General Nieuws Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 EN september 29, 2020
